Pailan Peng

Prof. Pailan Peng


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 November 2021 in Frontiers in Oncology
Verified
Journal Article
Open access
STShan Tian
Shan Tian
YCYinghao Cao
Yinghao Cao
YDYanran Duan
Yanran Duan
QLQi Liu
Qi Liu
PPPailan Peng
Pailan Peng
Aim: The Gustave Roussy Immune Score (GRIm-Score) was originally designed to select cancer patients for immunotherapy, and later was reported to be a novel prognostic scoring system in lung cancer and esophageal cancer. This study was aimed to determine the prognostic role and predictive performance of GRIm-Score in colorectal cancer (CRC) CRC patients. Methods: We conducted a single-institution study of 1,579 adult CRC patients receiving surgical removal, and those patients were divided into low GRIm-Score group (scores 0, 1) and high GRIm-Score group (scores 2, 3). Propensity score matching (PSM) was executed to balance the potential confounding factors between the two groups. Survival and time-dependent receiver operating characteristic (Td-ROC) analyses were applied to depict the prognostic role and predictive significance of GRIm-Score in CRC patients. Results: There were 200 cases CRC patients in high GRIm-Score group and 1,379 cases in low GRIm-Score group. CRC patients with high GRIm-Score correspond with higher level of CEA, CA125, and inflammatory indexes, such as NLR, PLR, SII, PNI, and ALRI. Correlation analysis exhibited that GRIm-Score correlated well with the established inflammatory indexes. Survival analysis revealed that CRC patients in high GRIm-Score group showed worse overall survival (OS, P <0.0001) and disease-free survival (DFS, P <0.0001) compared with those in low GRIm-Score group. Results from multivariate Cox regression implicated that high GRIm-Score was not only a potent prognostic index for unfavorable OS (HR = 1.622, 95%CI: 1.118–2.355, P = 0.0109), but also a potent risk factor for worse DFS (HR = 1.743, 95%CI: 1.188–2.558, P = 0.0045). Td-ROC analysis demonstrated that GRIm-Score exhibited the superior discriminatory power in the prediction of OS and DFS when compared to SII, PNI, and ALRI. Such strong associations between high levels of preoperative GRIm-Score and unfavorable survival outcomes remained robust after PSM analysis. Conclusion: GRIm-Score, a novel inflammatory and nutritional risk scoring system, is a potent prognostic index in CRC patients receiving surgical removal. GRIm-Score can be used as an effective and simplified risk stratification tool for postoperative survival prediction of CRC patients.

1 December 2022 in Journal of Hepatocellular Carcinoma
Verified
Journal Article
Open access
PDF file
STShan Tian
Shan Tian
JLJiao Li
Jiao Li
JXJiankang Xiang
Jiankang Xiang
PPPailan Peng
Pailan Peng
Background and Aim: This study was aimed to reveal the clinical relevance and immune correlation of the SLC10 family genes in liver cancer. Methods: A comprehensive bioinformatics analysis was utilized to determine the gene expression, genetic alterations, DNA methylation, clinical significance, survival association and immune correlation of seven SLC10 family genes in liver cancer. The multiplexed immunohistochemical technique was applied to determine the association between SLC10A3 protein expression and immune cells, and the correlation between SLC10A3 protein and immune checkpoints (PD1 and PD-L1) in a cohort of 32 individuals with liver cancer. Results: The expression of SLC10 family genes was different between normal liver tissues and malignant liver tissues. SLC10A5 showed the highest alteration rate (8%), followed by SLC10A3 (2.8%). Low expression of SLC10A1 was indicative of poor tumor grade and advanced tumor stage in liver cancer. Scatter plots uncovered that expression of SLC10A3 was inversely associated with SLC10A1 and SLC10A5 expression in liver cancer. The expression of SLC10A1 and SLC10A5 was strongly associated with their DNA methylation. SLC10A1 expression was a reliable genetic biomarker for the prediction of survival outcomes in liver cancer population. Expression of SLC10 family genes was remarkably linked with the abundance of most immune infiltrating cells in liver cancer, and SLC10A3 was the most significant member. The multiplexed immunohistochemical technique confirmed that there existed the significant correlations between SLC10A3 protein expression and CD4 T cells, CD20 B cells and the close association with PD-1 in the stromal area from malignant tissues. Conclusion: The expressions of SLC10 family genes were different between normal liver tissues and malignant liver tissues, and they were correlated with each other in liver cancer. SLC10A1 possesses the most significant correlation with survival outcomes. SLC10A3 exhibited the most significant relationship with immune cells, as revealed by bioinformatics analysis and multispectral imaging technique.

30 May 2023 in Journal of Cellular and Molecular Medicine
Verified
Journal Article
Open access
WRWan‐Yuan Ruan
Wan‐Yuan Ruan
LZLu Zhang
Lu Zhang
SLShan Lei
Shan Lei
ZZZhi rui Zeng
Zhi rui Zeng
YYYu‐Shi Yang
Yu‐Shi Yang
PPPailan Peng
Pailan Peng
Inflammation and ferroptosis crosstalk complexly with immune microenvironment of hepatocellular carcinoma (HCC), thus affecting the efficacy of immunotherapy. Herein, our aim was to identify the inflammation‐associated ferroptosis (IAF) biomarkers for contributing HCC. A total of 224 intersecting DEGs identified from different inflammation‐ and ferroptosis‐subtypes were set as IAF genes. Seven of them including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 were used for construction of a risk model which classified HCC patients into two groups (high and low risk). HCC patients in the high‐risk group exhibited shorter survival rate and higher immune score, and were predicted to have higher respond rate in immune checkpoint inhibition (ICI) therapy. Levels of the seven genes were significantly changed in HCC tissues in comparison to adjacent tissues. After inserting the gene expression into the risk model, we found that the risk model exhibited the higher diagnostic value for distinguish HCC tissues compared each single gene. Furthermore, HCC tissues from our research group with high‐risk score exhibited more cases of microsatellite instability (MSI), heavier tumour mutational burden (TMB), higher expression level of PDL1 and cells with CD8. Knockdown of APOA5 reduced HCC cell proliferation combining with elevating inflammation and ferroptosis levels. In conclusion, we considered APOA5 maybe a novel target for suppressing HCC via simultaneously elevating inflammation and ferroptosis levels, and signature constructed by seven IAF genes including ADH4, APOA5, CFHR3, CXCL8, FTCD, G6PD and PON1 can act as a biomarker for optimising the diagnosis, prognosis evaluation and immunotherapy options in HCC patients.

9 September 2022 in Frontiers in Immunology
Verified
Journal Article
Open access
ZZZhirui Zeng
Zhirui Zeng
CHChujiao Hu
Chujiao Hu
WRWanyuan Ruan
Wanyuan Ruan
JZJinjuan Zhang
Jinjuan Zhang
SLShan Lei
Shan Lei
TCTengxiang Chen
Tengxiang Chen
Isocitrate dehydrogenase (IDH1) is frequently mutated in glioma tissues, and this mutation mediates specific tumor-promoting mechanisms in glioma cells. We aimed to identify specific immune biomarkers for IDH1-mutation (IDH1mt) glioma. The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) were used to obtain RNA sequencing data and clinical characteristics of glioma tissues, while the stromal and immune scores of TCGA glioma tissues were determined using the ESTIMATE algorithm. Differentially expressed genes (DEGs), the protein–protein interaction(PPI) network, and least absolute shrinkage and selection operator (LASSO) and Cox regression analyses were used to select hub genes associated with stroma and immune scores and the prognoses of patients and to construct the risk model. The practicability and specificity of the risk model in both IDH1mt and IDH1-wildtype (wtIDH1) gliomas in TCGA and CGGA were evaluated. Molecular mechanisms, immunological characteristics and benefits of immune checkpoint blockade therapy in glioma tissues with IDH1mt were analyzed using GSEA, immunohistochemical staining, CIBERSORT, and T-cell dysfunction and exclusion (TIDE) analysis. The overall survival rate for IDH1mt-glioma patients with high stroma/immune scores was lower than that for those with low stroma/immune scores. A total of 222 DEGs were identified in IDH1mt glioma tissues with high stroma/immune scores. Among them, 72 genes had interactions in the PPI network, while three genes, HLA-DQA2, HOXA3, and SAA2, were selected as hub genes and used to construct risk models classifying patients into high- and low-risk score groups, followed by LASSO and Cox regression analyses. This risk model showed prognostic value in IDH1mt glioma in both TCGA and CCGA; nevertheless, the model was not suitable for wtIDH1 glioma. The risk model may act as an independent prognostic factor for IDH1mt glioma. IDH1mt glioma tissues from patients with high-risk scores showed more infiltration of M1 and CD8 T cells than those from patients with low-risk scores. Moreover, TIDE analysis showed that immune checkpoint blockade(ICB) therapy was highly beneficial for IDH1mt patients with high-risk scores. The risk model showed specific potential to predict the prognosis of IDH1mt-glioma patients, as well as guide ICB, contributing to the diagnosis and therapy of IDH1mt-glioma patients.

6 February 2026 in iScience
Verified
Journal Article
Open access
ZCZhonge Chen
Zhonge Chen
CSChengqin Sun
Chengqin Sun
YWYe Wang
Ye Wang
XDXiaojuan Duan
Xiaojuan Duan
HMHuaxing Ma
Huaxing Ma
PPPailan Peng
Pailan Peng
Hepatocellular carcinoma (HCC) is a common malignant tumor with a high mortality rate. High mitophagy levels can promote hepatic tumor progression; therefore, inhibiting mitophagy may be a promising therapeutic strategy. This study shows that minichromosome maintenance protein 3 (MCM3) was upregulated in HCC. Knocking down MCM3 suppressed the biological behaviors of tumor cells, promoted tumor cell apoptosis, and inhibited mitophagy. We found that USP1 binds to MCM3 and stabilizes it via deubiquitination of K48-linked ubiquitin chains. Excessive MCM3 proteins bind to Keap1, disrupting the Keap1-Nrf2 interaction and activating the Nrf2 signaling pathway to modulate mitophagy, promoting HCC progression. In addition, our in vivo experiments showed that MCM3 knockdown significantly suppressed xenograft tumor growth. In summary, MCM3 functions as a key oncoprotein. USP1-mediated deubiquitination of MCM3 influences the Keap1-Nrf2 axis, regulates mitophagy, and facilitates HCC progression. MCM3 may be a potential therapeutic target for liver cancer.

29 August 2025 in Medicine
Verified
Journal Article
Open access
XLXuelian Li
Xuelian Li
PPPailan Peng
Pailan Peng
FZFanghui Zhou
Fanghui Zhou
PPPailan Peng
Pailan Peng
Tumor microenvironment (TME) plays an important role in the prognosis of gastric cancer (GC). The aim of this study was to identify a TME-related gene signature and provide a basis for prognosis evaluation of GC. X-cell and cluster analyses were performed on 373 tumor samples from The Cancer Genome Atlas-Stomach Adenocarcinoma. Prognostic-related genes were screened using differential analysis. Univariate Cox analysis, LASSO regression, and multivariate Cox analysis were used to determine the candidate genes and construct the prognostic model. Independent prognostic and correlation analyses of clinical characteristics were performed. In the observational study, patients were divided into high- and low-risk groups according to the expression levels and risk coefficients of the 4 model genes. Mutation characteristics, immune cell differences, and TME differences between the high- and low-risk groups were analyzed. The expression levels of these key genes were subsequently validated using reverse transcription quantitative polymerase chain reaction and Western blotting. Two hundred and twenty-five candidate genes were obtained by differential analysis. Performed in the training set, and 4 hub genes (CTHRC1, APOD, S100A12, and ASCL2) were finally determined as prognostic biomarkers. The area under curve of the 1-, 3-, and 5-year receiver operating characteristic curves of the training set, test set, and validation set were all >0.6. There were significant differences in the frequency of some gene mutations and scores (immune score, matrix score, and ESTIMATE composite score) between the high- and low-risk groups. Reverse transcription quantitative polymerase chain reaction and Western blot analyses confirmed that CTHRC1, APOD, and S100A12 were significantly upregulated in the tumor group, whereas ASCL2 expression was significantly downregulated. We developed a TME-related gene signature that can predict the prognosis of patients with GC.